Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. (Q36067812)

12 August 2017

Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. (English)

1 reference

12 August 2017

1 reference

1 reference

Patricia I Dickson

1

1 reference

12 August 2017

Ilkka Kaitila

2

1 reference

12 August 2017

Paul Harmatz

3

1 reference

12 August 2017

Anton Mlikotic

4

1 reference

12 August 2017

Agnes H Chen

5

1 reference

12 August 2017

Alla Victoroff

6

1 reference

12 August 2017

Merry B Passage

7

1 reference

12 August 2017

Jacqueline Madden

8

1 reference

12 August 2017

Steven Q Le

9

1 reference

12 August 2017

David E Naylor

10

1 reference

12 August 2017

Mucopolysaccharidosis I Intrathecal Research Collaborative

11

1 reference

12 August 2017

26 July 2015

1 reference

Molecular Genetics and Metabolism

12 August 2017

1 reference

12 August 2017

116

1 reference

12 August 2017

69-74

1 reference

12 August 2017

1-2

1 reference

Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Diagnostic test for mucopolysaccharidosis. II. Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Enzyme-replacement therapy in mucopolysaccharidosis I.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4572891

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

23 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Enzyme replacement reduces neuropathology in MPS IIIA dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.07.005

Laminectomy and Posterior Cervical Plating for Multilevel Cervical Spondylotic Myelopathy and Ossification of the Posterior Longitudinal Ligament: Effects on Cervical Alignment, Spinal Cord Compression, and Neurological Outcome

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26260077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2015.07.005

1 reference

12 August 2017

1 reference

12 August 2017

1 reference